Uniformed Services, University of the Health Sciences, School of Medicine, Bethesda, MD, USA.
University of Massachusetts, Medical School/UMass Memorial Medical Center, Worcester, MA, USA.
Prog Neuropsychopharmacol Biol Psychiatry. 2019 Jun 8;92:235-242. doi: 10.1016/j.pnpbp.2019.01.016. Epub 2019 Jan 29.
In patients with schizophrenia, insomnia is a common yet often overlooked comorbidity. With sleep disturbances inextricably linked to increased severity of schizophrenia and worsening clinical outcomes, insomnia is an important therapeutic target within this patient population. Thus, through a review of the current literature, this paper reiterates the important etiological link between these two conditions, while evaluating the safety, efficacy, and limitations of current therapeutic options for the treatment of comorbid insomnia in schizophrenia. Despite the continued use of benzodiazepine receptor agonists (BZRAs) for insomnia, the use of other therapies such as Cognitive Behavioral Therapy for Insomnia (CBT-I) and suvorexant warrants increased consideration. More large-scale clinical trials are needed to assess the efficacy of such therapeutic options in the schizophrenia patient population.
在精神分裂症患者中，失眠是一种常见但常常被忽视的共病。睡眠障碍与精神分裂症严重程度的增加和临床结局的恶化密切相关，因此失眠是这一患者群体中的一个重要治疗靶点。因此，通过对当前文献的回顾，本文重申了这两种情况之间重要的病因学联系，同时评估了目前治疗精神分裂症共病失眠的治疗选择的安全性、有效性和局限性。尽管苯二氮䓬受体激动剂（BZRAs）仍被用于治疗失眠，但认知行为疗法（CBT-I）和苏沃雷生等其他疗法的应用也值得更多关注。需要进行更多大规模的临床试验来评估这些治疗选择在精神分裂症患者群体中的疗效。
